Key Insights

Highlights

Success Rate

81% trial completion

Published Results

11 trials with published results (41%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

14.8%

4 terminated out of 27 trials

Success Rate

81.0%

-5.6% vs benchmark

Late-Stage Pipeline

52%

14 trials in Phase 3/4

Results Transparency

65%

11 of 17 completed with results

Key Signals

11 with results81% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (2)
P 1 (3)
P 2 (3)
P 3 (13)
P 4 (1)

Trial Status

Completed17
Terminated4
Unknown2
Recruiting2
Withdrawn1
Not Yet Recruiting1

Trial Success Rate

81.0%

Benchmark: 86.5%

Based on 17 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT06966284Recruiting

A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection

NCT07386912Not Yet Recruiting

Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE -

NCT06804096Phase 4Recruiting

Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)

NCT05531149Phase 3Terminated

Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia

NCT04779242Phase 3Completed

Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia

NCT05629741Phase 1Terminated

A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101

NCT05417997Phase 3Completed

Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients

NCT03158727Phase 1CompletedPrimary

Cx611-0204 SEPCELL Study

NCT04952337Unknown

Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)

NCT03862040Phase 1TerminatedPrimary

Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia

NCT02493764Phase 3CompletedPrimary

Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

NCT03752320Unknown

Multiplex Polymerase Chain Reaction in Postoperative Pneumonia After Thoracic Surgery

NCT00107952Phase 3CompletedPrimary

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

NCT02531438Phase 3CompletedPrimary

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

NCT00124020Phase 3CompletedPrimary

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

NCT00645619Withdrawn

Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children

NCT01570192Phase 2TerminatedPrimary

Clinical Trials to Reduce the Risk of Antimicrobial Resistance

NCT00509106Phase 3CompletedPrimary

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

NCT00621504Phase 3CompletedPrimary

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

NCT00451386Phase 2Completed

Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)

Scroll to load more

Research Network

Activity Timeline